← All trials
NCT05191225
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 28, 2021
- Primary completion
- Mar 31, 2022
- Completion date
- Dec 31, 2022
- First posted
- Jan 13, 2022
- Last posted
- Mar 31, 2022
- Enrollment
- 48
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Bioaraba Health Research InstituteLead sponsor
- Bioaraba Health Research InstituteOverall official - principal investigator
- Bioaraba Health Research InstituteSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.